What is "pidilizumab"

Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, but this is currently uncertain. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.